Article
Immunology
Kirill Nemirov, Pierre Authie, Philippe Souque, Fanny Moncoq, Amandine Noirat, Catherine Blanc, Maryline Bourgine, Laleh Majlessi, Pierre Charneau
Summary: Dengue virus (DENV) is a major cause of dengue fever, including severe forms such as hemorrhagic dengue and dengue shock syndrome. Despite intensive vaccine research, a universally accepted vaccine against dengue fever has not been developed yet. This study developed a tetravalent T-cell vaccine candidate against DENV, which showed significant protective effects against all four DENV serotypes in a preclinical infection model.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Infectious Diseases
Alejandro Marin-Lopez, Junjun Jiang, Yuchen Wang, Yongguo Cao, Tyler MacNeil, Andrew K. Hastings, Erol Fikrig
Summary: Dengue virus is a flavivirus transmitted by Aedes aegypti mosquitoes, placing nearly half of the world's population at risk for infection. The study identified two mosquito proteins, AeSNAP and ATPase, that play a role in DENV viral dissemination, suggesting potential targets for combating dengue.
PLOS NEGLECTED TROPICAL DISEASES
(2021)
Article
Cell Biology
Antonio G. Dias, Caroline Atyeo, Carolin Loos, Magelda Montoya, Vicky Roy, Sandra Bos, Parnal Narvekar, Tulika Singh, Leah C. Katzelnick, Guillermina Kuan, Douglas A. Lauffenburger, Angel Balmaseda, Galit Alter, Eva Harris
Summary: This study used a systems serology approach to analyze a pediatric cohort in Nicaragua and found that specific antibody immune responses may be associated with protection against dengue fever, which could be applied in the design and evaluation of vaccines.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Immunology
Kassandra L. Carpio, Alan D. T. Barrett
Summary: The Flavivirus genus includes many important human pathogens, with NS1 protein playing a crucial role as a diagnostic marker for flavivirus infection. Its roles in disease pathogenesis and protective immunity make NS1 an excellent target for candidate vaccines.
Review
Chemistry, Medicinal
Podila Naresh, Shyam Sunder Pottabatula, Jubie Selvaraj
Summary: This study presents a comprehensive overview of the latest understanding of the use of small molecules as fusion inhibitors in the treatment of flavivirus-like dengue. Despite vaccines being available for viral infections such as yellow fever and Japanese encephalitis, dengue remains a significant life-threatening illness worldwide with no antiviral treatment currently available.
MINI-REVIEWS IN MEDICINAL CHEMISTRY
(2022)
Review
Immunology
Jue Hou, Weijian Ye, Jianzhu Chen
Summary: Dengue is a common mosquito-borne disease caused by four closely related viruses. Developing a vaccine that can protect against all four virus strains without adverse effects is a challenge. Several tetravalent live attenuated vaccine candidates have entered clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Virology
Guntur Fibriansah, Xin-Ni Lim, Shee-Mei Lok
Summary: The four serotypes of dengue virus exhibit different morphologies, such as compact spherical, bumpy spherical, and non-spherical clubshape morphologies. The inefficient maturation process leads to the presence of partially immature but infectious viral particles that have different antigenicity profiles. Understanding the molecular determinants and environmental conditions that induce morphological changes in the virus, as well as how potent antibodies interact with these particles, is crucial for designing effective therapeutics or vaccines. Multiple techniques have been used to investigate the structural changes in DENV, revealing key residues and interactions playing important roles in these changes.
Review
Pathology
Gillian L. Hale
Summary: Flaviviruses are single-stranded RNA viruses that pose an important and growing burden to human health, with over 3 billion individuals living in endemic areas. These viruses exploit global travel to expand their distribution and cause severe diseases in humans. They can be grouped based on their vector and pathogenicity. Mosquito-borne flaviviruses cause a spectrum of diseases including encephalitis, hepatitis, vascular shock syndrome, congenital abnormalities, and fetal death. Neurotropic infections such as Zika virus and West Nile virus infect neurons, leading to meningoencephalitis. Yellow fever virus and dengue virus, belonging to the hemorrhagic fever clade, infect hepatocytes and cells of the reticuloendothelial system respectively, resulting in plasma cell leakage and shock syndrome. Zika virus also causes congenital infections and fetal death. Diagnostic testing for flaviviruses includes detecting viral RNA in serum, viral isolation by cell culture, and histopathologic evaluation with immunohistochemistry and molecular testing. This review focuses on mosquito-borne flaviviruses and discusses their transmission, the role of travel in geographic distribution and epidemic emergence, and their clinical and histopathologic features. Preventive strategies such as vector control and vaccination are also discussed.
Article
Biology
Dongsheng Li, Min-Hsuan Lin, Daniel J. Rawle, Hongping Jin, Zhonglan Wu, Lu Wang, Mary Lor, Mazhar Hussain, John Aaskov, David Harrich
Summary: Li et al. have developed a DENV-derived defective interfering particle (DIP) production cell line that can stably produce infectious virus-free DIPs. The DENV DIPs produced from this system can potently inhibit replication of all DENV serotypes in cells and have the potential to be repurposed to make antiviral DIPs for other RNA viruses.
COMMUNICATIONS BIOLOGY
(2021)
Article
Virology
Karin Stiasny, Stefan Malafa, Stephan W. Aberle, Iris Medits, Georgios Tsouchnikas, Judith H. Aberle, Heidemarie Holzmann, Franz X. Heinz
Summary: In this study, a new IgM assay format was developed for specific diagnosis of TBE, Zika, and dengue virus infections. The IgM response proved to be highly specific for TBE and Zika infections, while cross-reactive IgM antibodies were detected in cases of primary dengue virus infections. Despite the presence of cross-reactive IgM, the assay allowed for serotype-specific diagnosis of recent dengue virus infections in most cases.
Article
Virology
Connor A. P. Scott, Alberto A. Amarilla, Summa Bibby, Natalee D. Newton, Roy A. Hall, Jody Hobson-Peters, David A. Muller, Keith J. Chappell, Paul R. Young, Naphak Modhiran, Daniel Watterson
Summary: The study revealed that immunization with partially mature bDENV-2 generated stronger immune responses and better protection against homotypic DENV-2 challenge in mice. Additionally, mature bDENV-2 vaccinated mice showed reduced in vitro ADE at subneutralising serum concentrations, suggesting potential safety benefits of mature DENV-based vaccines.
Article
Medicine, General & Internal
Joseph R. Biggs, Ava Kristy Sy, Katharine Sherratt, Oliver J. Brady, Adam J. Kucharski, Sebastian Funk, Mary Anne Joy Reyes, Mary Ann Quinones, William Jones-Warner, Ferchito L. Avelino, Nemia L. Sucaldito, Amado O. Tandoc, Eva Cutiongco-de la Paz, Maria Rosario Z. Capeding, Carmencita D. Padilla, Julius Clemence R. Hafalla, Martin L. Hibberd
Summary: Through studying dengue case data in 13 cities in the Philippines, it was found that indicators such as the mean age of primary infections and the mean age of those reporting with warning signs represent superior indicators of the dengue force of infection compared to crude incidence. This study provides a framework for national dengue surveillance agencies to routinely monitor transmission and target control interventions to the populations most in need.
Article
Microbiology
Haiyan Ye, Xiaoqiong Duan, Min Yao, Lan Kang, Yujia Li, Shilin Li, Bin Li, Limin Chen
Summary: The research found that DENV infection can increase the expression of USP18, which in turn promotes the replication of DENV-2. Silencing USP18 can enhance the resistance of IFN-alpha to DENV-2.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Immunology
Scott B. Halstead
Summary: In tropical and subtropical countries, four dengue viruses can cause severe disease, but the development of vaccines has been slow. Three tetravalent dengue vaccines have reached phase 3 clinical trials, but their effectiveness varies against different dengue virus types. A novel vaccine developed by the US National Institutes of Health has shown protective effects against dengue viruses in seronegative individuals during late-stage trials.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Medicine, Research & Experimental
Wen-Hung Wang, Aspiro Nayim Urbina, Chih-Yen Lin, Zih-Syuan Yang, Wanchai Assavalapsakul, Arunee Thitithanyanont, Po-Liang Lu, Yen-Hsu Chen, Sheng-Fan Wang
Summary: The development of dengue vaccines is crucial in preventing and controlling the global health threat caused by Dengue virus. Current approved vaccines have demonstrated low efficacy in certain populations, leading to ongoing investigation and development of novel strategies for dengue vaccines.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
